药品监管对中国制药企业绩效的影响及其机制初探  

A Preliminary Study on the Impact and Its Mechanism of Pharmaceutical Regulation on the Firm Performance

作　　者：张源 ZHANG Yuan(Business School, Renmin University of China, Beijing 100872, China)

机构地区：[1]中国人民大学商学院,北京100872

出　　处：《中国药学杂志》2019年第6期506-510,共5页Chinese Pharmaceutical Journal

摘　　要：目的探讨药品监管对制药产业发展的影响及其机制。方法基于1996~2016年间中国制药产业数据,以药品监管强度为自变量,医药制造业利润率为因变量,研发创新和企业投资为中介变量,进行多元线性回归。结果药品监管强度与利润率为显著正相关,研发创新起到显著的中介作用。结论药品监管刺激了研发投入,促进了技术创新,技术创新的成果会增加企业绩效,而技术创新带来的企业绩效增加,完全弥补了规制成本所导致的企业绩效降低,结果增加了总的绩效。OBJECTIVE To study the impact and its mechanism of pharmaceutical regulation on the firm performance. METHODS To make the multiple regression analysis with the pharmaceutical regulation intensity as independent variable, profit rate as dependent variable, R&D innovation and firm investment as intervening variable, based on the pharmaceutical industry data of China. RESULTS The relationship between the pharmaceutical regulation intensity and profit rate is significantly positive correlation, for which the R&D innocation plays a role of mediation. CONCLUSION Pharmaceutical regulation stimulates the R&D revenue and enhances technical innovation, and thus the innovation achievement enhances the firm performance. The increase of firm performance brought by innovation compensates the drop by regulation cost.

关 键 词：药品监管 技术创新 企业绩效 制度基础观 

分 类 号：R951[医药卫生—药学]